RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.

Chunyang Jin RTI Expert Headshot
Experts

Chunyang Jin

Senior Research Chemist

Education

PhD, Organic Chemistry, New Mexico State University
MS, Bioorganic Chemistry, Fudan University, China
BS, Chemistry, Fudan University, China

Chunyang Jin, PhD, has more than 15 years of experience in synthetic organic chemistry and medicinal chemistry. He leads a program on the development of medications for CNS disorders targeting G protein-coupled receptors (GPCRs).

Dr. Jin has conducted medicinal chemistry lead optimization campaigns for a variety of biological ligands and receptors. His current research focuses on the development of small-molecule probes for the study of GPCRs, including the orphan receptor GPR88 and neuropeptide receptor RXFP3. Dr. Jin’s research is supported by funding from the National Institute of Mental Health and the National Institute on Alcohol Abuse and Alcoholism.

Dr. Jin has published more than 30 peer-reviewed publications and presented at many national meetings. He is an active member of the Society for Neuroscience, American Chemical Society, and Research Society on Alcoholism.

Expertise
  • Medicinal chemistry
  • G protein-coupled receptors
  • Drug treatments for alcoholism
Press Info

For media inquiries or to request an interview, contact our Media Relations team.

Publications

View All Publications
Article

Development of diphenyl-1,2,4-oxadiazole analogues as allosteric modulators of the rxfp3 receptor: Evaluation of importance of the n-substituted-2-pyrrolidone moiety in rlx-33

April 2025
Article

Targeting the relaxin-3/RXFP3 system: A patent review for the last two decades

April 2024
Article

Design, synthesis, and structure–activity relationship studies of novel GPR88 agonists (4-substituted-phenyl)acetamides based on the reversed amide scaffold

January 2024
Article

Novel RXFP3 negative allosteric modulator RLX-33 reduces alcohol self-administration in rats

October 2023

Related Capabilities

Focus Area

Behavioral Health Research
Focus Area

Substance Use Research
Focus Area

Treating Substance Use and Misuse
Solution

Medicinal Chemistry

Get in Touch

To speak to this expert or inquire about RTI services, you can reach us at +1 919 541 6000 or use the contact form below. For media inquiries, please reach out to our Media Relations team at news@rti.org.

Blue background circle graphics